CY1488A - Process for the production of human mono-clonal antibodies - Google Patents
Process for the production of human mono-clonal antibodies Download PDFInfo
- Publication number
- CY1488A CY1488A CY1488A CY148889A CY1488A CY 1488 A CY1488 A CY 1488A CY 1488 A CY1488 A CY 1488A CY 148889 A CY148889 A CY 148889A CY 1488 A CY1488 A CY 1488A
- Authority
- CY
- Cyprus
- Prior art keywords
- cell
- hybridoma cell
- cell line
- human
- substance
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 210000004027 cell Anatomy 0.000 claims description 123
- 210000004408 hybridoma Anatomy 0.000 claims description 66
- 239000000126 substance Substances 0.000 claims description 37
- 210000004698 lymphocyte Anatomy 0.000 claims description 25
- 239000002609 medium Substances 0.000 claims description 24
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 23
- 230000004927 fusion Effects 0.000 claims description 23
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 23
- 238000000338 in vitro Methods 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 13
- 102000018358 immunoglobulin Human genes 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 10
- 230000016784 immunoglobulin production Effects 0.000 claims description 8
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 claims description 7
- 229960005508 8-azaguanine Drugs 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 210000003917 human chromosome Anatomy 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 230000007910 cell fusion Effects 0.000 claims 4
- 241001529936 Murinae Species 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241000700605 Viruses Species 0.000 description 11
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/166—Animal cells resulting from interspecies fusion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH409/82A CH652145A5 (de) | 1982-01-22 | 1982-01-22 | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1488A true CY1488A (en) | 1989-12-08 |
Family
ID=4186382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY1488A CY1488A (en) | 1982-01-22 | 1989-12-08 | Process for the production of human mono-clonal antibodies |
Country Status (17)
Families Citing this family (179)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247538A (en) * | 1982-05-21 | 1988-12-28 | Mark C. Glassy | Human-human hybridomas for solid tumors |
| US4613576A (en) * | 1983-03-09 | 1986-09-23 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cancer cells |
| EP0148644A3 (en) * | 1984-01-06 | 1987-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | A novel fusion partner and its products |
| US4634666A (en) * | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US4764465A (en) * | 1984-04-26 | 1988-08-16 | Cetus Corporation | Human monoclonal antibody against group A red blood cells |
| DE3581400D1 (de) * | 1984-09-28 | 1991-02-21 | Teijin Ltd | Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper. |
| JPS6187630A (ja) * | 1984-10-08 | 1986-05-06 | Teijin Ltd | 単純ヘルペスウイルスに対するヒトモノクロ−ナル抗体及びその製造法 |
| US4693975A (en) * | 1984-11-20 | 1987-09-15 | The Wistar Institute | Human hybridroma fusion partner for production of human monoclonal antibodies |
| JPS61155398A (ja) * | 1984-12-28 | 1986-07-15 | Teijin Ltd | 抗緑膿菌ヒトモノクロ−ナル抗体及びその製造法並びにそれを有効成分とする治療剤 |
| USH1198H (en) | 1985-04-26 | 1993-06-01 | Cetus Corporation | Pseudomonas aeruginosa type-specific human monoclonal antibodies, their preparation and use |
| US4677070A (en) * | 1985-04-26 | 1987-06-30 | Cetus Corporation | Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use |
| CH670098B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1985-05-23 | 1989-05-12 | ||
| JPH0720885B2 (ja) * | 1985-09-27 | 1995-03-08 | 帝人株式会社 | 単純ヘルペスウイルス感染症の予防又は治療剤 |
| NZ218499A (en) * | 1985-12-10 | 1990-04-26 | Genetic Systems Corp | Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods |
| EP0261233A4 (en) * | 1986-04-01 | 1988-08-29 | Genelabs Inc | IMMORTALIZED TISSUE CELLS WITH VIRAL SPECIFICITY. |
| WO1987005929A1 (en) * | 1986-04-01 | 1987-10-08 | Genelabs Incorporated | Immortalized cells which produce tissue-specific products |
| US5565354A (en) * | 1986-09-05 | 1996-10-15 | Sandoz Ltd. | Production of human monoclonal antibodies specific for hepatitis B surface antigen |
| US5646041A (en) * | 1987-02-12 | 1997-07-08 | Harfeldt; Elisabeth | Monoclonal antibody to herpes simplex virus and cell line producing same |
| US5001065A (en) * | 1987-05-27 | 1991-03-19 | Cetus Corporation | Human cell line and triomas, antibodies, and transformants derived therefrom |
| JPH01101896A (ja) * | 1987-10-14 | 1989-04-19 | Teijin Ltd | カンジダに対するヒト・モノクローナル抗体とその製造法 |
| US5215913A (en) * | 1987-11-30 | 1993-06-01 | Roger Williams General Hospital | IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use |
| IT1226477B (it) * | 1988-07-04 | 1991-01-16 | Genetik Mab S R L | Linee cellulari n omas quale un mezzo per immortalare cellule produttrici di sostanze di qualunque specie animale. |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2535455B2 (ja) * | 1991-02-07 | 1996-09-18 | 帝人株式会社 | サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ |
| KR100255717B1 (ko) * | 1991-07-15 | 2000-05-01 | 그레이엄 브레레톤 | 항체의 생산방법 |
| JPH05276984A (ja) * | 1991-09-05 | 1993-10-26 | Teijin Ltd | カンジダに対するヒト・モノクローナル抗体を産生するハイブリドーマ |
| JPH05260961A (ja) * | 1992-05-21 | 1993-10-12 | Teijin Ltd | サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ |
| FI940811A0 (fi) * | 1992-06-26 | 1994-02-21 | Aetsrn | Ihmisen monoklonaalisia anti-Rhesus(D) -vasta-aineita ja niitä tuottavat solulinjat |
| EP0583980A1 (en) * | 1992-08-20 | 1994-02-23 | Eli Lilly And Company | Method for generating monoclonal antibodies from rabbits |
| AU684455B2 (en) * | 1992-11-06 | 1997-12-18 | Sandoz Ltd. | Production of human monoclonal antibodies active against hepatitis B surface antigen |
| US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
| AU2527397A (en) * | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
| EP2172478A3 (en) | 1997-02-07 | 2010-07-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Activity-dependent neurotrophic factor III (ADNF III) |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| WO2001032712A2 (en) * | 1999-11-03 | 2001-05-10 | Maxygen, Inc. | Antibody diversity generation |
| US7060802B1 (en) * | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| AU2002256292C1 (en) | 2001-04-19 | 2008-08-14 | The Regents Of The University Of California | In vivo incorporation of unnatural amino acids |
| US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| AU2002340169A1 (en) * | 2001-10-11 | 2003-06-17 | Protein Design Labs Inc. | Identifying anti-tumor targets or agents by lipid raft immunization and proteomics |
| ATE541047T1 (de) | 2002-08-01 | 2012-01-15 | Univ California | Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| ES2632216T3 (es) | 2003-05-19 | 2017-09-11 | Prothena Biosciences Limited | Fragmentos truncados de la alfa-sinucleína en la enfermedad de cuerpos de Lewy |
| WO2005018539A2 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| US7888063B2 (en) | 2003-06-18 | 2011-02-15 | The Scripps Research Institute | Unnatural reactive amino acid genetic code additions |
| CA2568015C (en) | 2004-05-25 | 2013-08-27 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| US7935790B2 (en) * | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
| US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
| LT2682126T (lt) | 2005-01-27 | 2017-02-27 | Children`s Hospital & Research Center at Oakland | Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų |
| WO2007094754A2 (en) | 2005-01-27 | 2007-08-23 | The Regents Of The University Of Califordnia | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| EP2441471B1 (en) | 2005-03-08 | 2014-10-08 | MedImmune, LLC | Reassortant influenza viruses |
| US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| ES2346691T3 (es) * | 2005-08-02 | 2010-10-19 | Xbiotech, Inc | Diagnostico, tratamiento y prevencion de trastornos vasculares usando autoanticuerpos il-1alfa. |
| EP1934867A2 (en) * | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| US20100151495A9 (en) * | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| US8173425B2 (en) * | 2006-04-13 | 2012-05-08 | N{dot over (a)}omasa Yamamoto | Fusion partner cells |
| WO2007127335A2 (en) * | 2006-04-27 | 2007-11-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways |
| US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| CN107158376A (zh) * | 2006-05-22 | 2017-09-15 | 埃克斯生物科技公司 | 使用抗IL‑1α抗体治疗癌症 |
| ES2612383T3 (es) | 2006-07-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | WSX-1/IL-27 como una diana para respuestas antiinflamatorias |
| US7939636B2 (en) * | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
| US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| WO2008083169A2 (en) * | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
| US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
| US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| EP2124998B8 (en) * | 2006-12-27 | 2015-05-06 | The Johns Hopkins University | Methods for detecting inflammation and auto-immune diseases |
| LT3067066T (lt) | 2007-02-23 | 2019-06-25 | Prothena Biosciences Limited | Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas |
| CA2678963C (en) | 2007-02-23 | 2018-05-01 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20090081659A1 (en) | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| EP1975184A3 (en) | 2007-03-26 | 2008-11-26 | Cell Signaling Technology, Inc. | Serine or threonine phosphorylation sites |
| US20080238709A1 (en) * | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
| EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| EP1983002A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| US8715743B2 (en) | 2007-08-03 | 2014-05-06 | Musc Foundation For Research Development | Human monoclonal antibodies and methods for producing the same |
| JP5485152B2 (ja) | 2007-08-15 | 2014-05-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 単一特異性および多特異性抗体ならびに使用方法 |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| EP2185196B1 (en) | 2007-08-27 | 2014-06-11 | Longhorn Vaccines & Diagnostics, LLC | Immunogenic compositions and methods |
| WO2009085355A2 (en) | 2007-10-01 | 2009-07-09 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| JP2010540953A (ja) | 2007-10-05 | 2010-12-24 | ナショナル インスティテュート フォー バイオプロセッシング リサーチ アンド トレーニング リミテッド | 膵炎、敗血症および膵臓癌のためのグリコシル化マーカー |
| EP2062920A3 (en) | 2007-11-21 | 2009-06-17 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways |
| US20090169549A1 (en) * | 2007-12-19 | 2009-07-02 | The Board Of Regents Of The University Of Texas System | Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use |
| US20090220991A1 (en) * | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| EP3023502A1 (en) | 2008-04-10 | 2016-05-25 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
| KR20170005166A (ko) | 2008-05-30 | 2017-01-11 | 엑스바이오테크, 인크. | 인터류킨-1 알파 항체 및 그의 사용 방법 |
| CN102112878A (zh) * | 2008-06-06 | 2011-06-29 | 国立大学法人富山大学 | 用于检测流感病毒的装置 |
| SG192501A1 (en) | 2008-07-11 | 2013-08-30 | Medimmune Llc | Influenza hemagglutinin and neuraminidase variants |
| CN102209557A (zh) * | 2008-09-12 | 2011-10-05 | 埃克斯生物科技公司 | 靶向病原性单核细胞 |
| US20100260752A1 (en) | 2009-01-23 | 2010-10-14 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria |
| CA2752205A1 (en) | 2009-02-12 | 2010-08-19 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
| IN2012DN02753A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| CN102946904A (zh) | 2010-06-18 | 2013-02-27 | 埃克斯生物科技公司 | 关节炎治疗 |
| MX388939B (es) | 2010-08-23 | 2025-03-20 | Xbiotech Inc | Anticuerpo anti-il-1a para usarse en el tratamiento de cáncer metastásico. |
| KR20200145867A (ko) | 2010-12-06 | 2020-12-30 | 시애틀 지네틱스, 인크. | Ｌｉｖ-１에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| EP3417879A1 (en) | 2011-04-01 | 2018-12-26 | XBiotech, Inc | Treatment for dermatological pathologies |
| EP2750709B1 (en) | 2011-09-23 | 2018-08-15 | XBiotech, Inc | Cachexia treatment |
| WO2013112916A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| UA105278C2 (ru) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| KR102296017B1 (ko) | 2012-10-04 | 2021-09-01 | 얀센 바이오테크 인코포레이티드 | 혈관 질환 및 이에 따른 합병증 치료 |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| KR102313513B1 (ko) | 2013-03-13 | 2021-10-15 | 프로테나 바이오사이언시즈 리미티드 | Tau 면역치료제 |
| WO2015003114A1 (en) | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
| WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
| US9951131B2 (en) | 2013-07-12 | 2018-04-24 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
| PT3041513T (pt) | 2013-09-08 | 2020-09-07 | Kodiak Sciences Inc | Conjugados de polímeros zwiteriónicos com fator viii |
| CA2938931A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
| TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| WO2015136469A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| KR102210104B1 (ko) | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| CA2984249A1 (en) | 2015-04-29 | 2016-11-03 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| EP3294448A4 (en) | 2015-05-14 | 2018-12-12 | Longhorn Vaccines and Diagnostics, LLC | Rapid methods for the extraction of nucleic acids from biological samples |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| CA2998716A1 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| US11066465B2 (en) | 2015-12-30 | 2021-07-20 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| MY191649A (en) | 2016-03-04 | 2022-07-05 | Jn Biosciences Llc | Antibodies to tigit |
| WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| KR102471787B1 (ko) | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| CU24538B1 (es) | 2016-05-02 | 2021-08-06 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7 |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| EP3478716A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| KR20190025689A (ko) | 2016-07-06 | 2019-03-11 | 프로테나 바이오사이언시즈 리미티드 | 전체 및 s129 인산화된 알파-시누클레인을 검출하기 위한 검정 |
| MX2019009798A (es) | 2017-02-16 | 2020-01-30 | Xbiotech Inc | Tratamiento de la hidradenitis supurativa. |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| KR102344616B1 (ko) | 2017-05-30 | 2021-12-31 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 | 항-더블코르틴-유사 키나제 1 항체 및 사용 방법 |
| EP3655031A1 (en) | 2017-07-21 | 2020-05-27 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neisseria meningitidis immunogenic compositions |
| JP7292569B2 (ja) | 2017-10-06 | 2023-06-19 | ノボ ノルディスク エー／エス | トランスサイレチンを検出する方法 |
| US11292846B2 (en) | 2017-11-02 | 2022-04-05 | Bayer Aktiengesellschaft | Bispecific antibodies binding ALK-1 and BMPR-2 |
| JP2021514656A (ja) | 2018-03-02 | 2021-06-17 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート |
| JP2022510634A (ja) | 2018-11-28 | 2022-01-27 | フォーティ セブン， インコーポレイテッド | 除去レジメンに抵抗性の遺伝的に改変されたｈｓｐｃ |
| TW202045206A (zh) | 2019-02-27 | 2020-12-16 | 美商健生生物科技公司 | 抗體調配物 |
| WO2020180819A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| BR112022013589A2 (pt) | 2020-01-08 | 2022-09-13 | Regeneron Pharma | Tratamento da fibrodisplasia ossificante progressiva |
| WO2021211924A1 (en) | 2020-04-16 | 2021-10-21 | Janssen Biotech, Inc. | Treatment of atopic dermatitis |
| IL298111A (en) | 2020-06-02 | 2023-01-01 | Arcus Biosciences Inc | Antibodies to tigit |
| KR20230026489A (ko) | 2020-06-24 | 2023-02-24 | 프로테나 바이오사이언시즈 리미티드 | 소르틸린을 인지하는 항체 |
| GB202508531D0 (en) | 2020-10-20 | 2025-07-16 | Longhorn Vaccines & Diagnostics Llc | Immunogenic antigens |
| CN116745323A (zh) | 2021-01-22 | 2023-09-12 | 拜耳股份有限公司 | Lrrc15抗体及其缀合物 |
| WO2022265912A1 (en) | 2021-06-16 | 2022-12-22 | Gundersen Lutheran Medical Foundation, Inc. | Antibodies targeting an amphiregulin-derived cell surface neo-epitope |
| WO2025006737A1 (en) | 2023-06-30 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine |
| EP4527851A1 (en) | 2023-09-22 | 2025-03-26 | Bayer Aktiengesellschaft | Bispecific antibodies binding ltbr and lrrc15 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2757169A1 (de) * | 1977-12-22 | 1979-07-05 | Hoechst Ag | Verfahren zur gewinnung insulin produzierender tierischer zellen |
| ZA806506B (en) * | 1979-11-01 | 1981-09-30 | Bio Response Inc | A method for production of monoclonal antibodies |
| GB2079313A (en) * | 1980-07-07 | 1982-01-20 | Nat Res Dev | Improvements in or relating to rat myeloma cell lines |
| DE3167442D1 (en) * | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
| JPS57502090A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1980-07-18 | 1982-11-25 | ||
| JPS586475B2 (ja) * | 1980-08-23 | 1983-02-04 | 株式会社 林原生物化学研究所 | ヒト絨毛性性腺刺激ホルモンの製造方法 |
| JPS6045849B2 (ja) * | 1980-08-25 | 1985-10-12 | 林原 健 | ヒトエリトロポエチンの製造方法 |
| JPS5743696A (en) * | 1980-08-27 | 1982-03-11 | Hayashibara Biochem Lab Inc | Preparation of human luteinizing hormone |
| JPS585671B2 (ja) * | 1980-08-27 | 1983-02-01 | 株式会社 林原生物化学研究所 | ヒト卵胞刺激ホルモンの製造方法 |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4529694A (en) * | 1982-04-16 | 1985-07-16 | The Children's Medical Center Corporation | Cell fusion |
-
1982
- 1982-01-22 CH CH409/82A patent/CH652145A5/de not_active IP Right Cessation
-
1983
- 1983-01-15 DE DE19833301249 patent/DE3301249A1/de active Granted
- 1983-01-19 GB GB08301384A patent/GB2113715B/en not_active Expired
- 1983-01-20 SE SE8300290A patent/SE502344C2/sv not_active IP Right Cessation
- 1983-01-20 IL IL67721A patent/IL67721A/xx unknown
- 1983-01-20 FI FI830190A patent/FI83538C/fi not_active IP Right Cessation
- 1983-01-20 FR FR8300850A patent/FR2522679B1/fr not_active Expired
- 1983-01-20 US US06/459,731 patent/US4634664A/en not_active Expired - Lifetime
- 1983-01-20 DK DK23183A patent/DK23183A/da not_active Application Discontinuation
- 1983-01-21 IT IT19234/83A patent/IT1160468B/it active
- 1983-01-21 JP JP58009241A patent/JPS58128323A/ja active Granted
- 1983-01-21 AT AT0019583A patent/AT388932B/de not_active IP Right Cessation
-
1987
- 1987-12-30 MY MY169/87A patent/MY8700169A/xx unknown
-
1989
- 1989-04-27 SG SG281/89A patent/SG28189G/en unknown
- 1989-05-16 KE KE3884A patent/KE3884A/xx unknown
- 1989-06-29 HK HK525/89A patent/HK52589A/xx not_active IP Right Cessation
- 1989-12-08 CY CY1488A patent/CY1488A/en unknown
-
1990
- 1990-10-03 JP JP2267500A patent/JPH03236794A/ja active Granted
-
1991
- 1991-05-30 JP JP3157731A patent/JPH0789909B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4634664A (en) | Process for the production of human mono-clonal antibodies | |
| EP0014519B1 (en) | Cell lines, process for preparing them and process for producing antibodies | |
| US5627052A (en) | Methods for the production of proteins with a desired function | |
| EP0488470B1 (en) | Method for the production of antibodies | |
| US5215913A (en) | IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use | |
| US4594325A (en) | High fusion frequency fusible lymphoblastoid cell line | |
| US4574116A (en) | Methods and cell lines for immortalization and monoclonal antibody production by antigen-stimulated B-lymphocytes | |
| US5114847A (en) | Process for the production of permanently culturable animal and human cell lines and the use thereof | |
| Melamed et al. | Requirements for the establishment of heterohybridomas secreting monoclonal human antibody to rhesus (D) blood group antigen | |
| Dorfman | The optimal technological approach to the development of human hybridomas | |
| Diamond et al. | Monoclonal antibodies | |
| Scharff et al. | Monoclonal antibodies | |
| Abrams et al. | [10] Optimal strategies for developing human—human monoclonal antibodies | |
| Schönherr et al. | Antibody engineering, a strategy for the development of monoclonal antibodies | |
| Lindl | Development of human monoclonal antibodies: A review | |
| JP3043023B2 (ja) | ハイブリドーマ | |
| Bartal et al. | Current methodologies in hybridoma formation | |
| Scharff et al. | Present status and future prospects for the hybridoma technology | |
| RU1801117C (ru) | Способ получения монокло- нального антитела к моноклональному антителу к белку т4 лимфоцита человека, культивируемая клетка гибридомы jthfs-про- дуцентмоноклонального антитела к моноклональному антителу к белку т4 лимфоцита чело- века, культивируемая клетка гибридомы jti-if3-f5 - продуцент моноклонального антитела к моноклональному антителу к белку т4 лимфоцитачеловека, культивируемая клетка гибридомы jti-id7 - про- дуцент моноклонального антитела к моноклональному антителу к белку т4 лимфоцита человека, культивируемая клетка гибридомы jt2-n15 - продуцент моноклонального антитела к моноклональному антителу к белку т4 лимфоцитачеловека | |
| CS276448B6 (cs) | Způsob výroby permanentních buněčných lini-í živočišného i lidského původu | |
| CY1644A (en) | Monoclonal antibodies | |
| Shoenfeld et al. | The Production of Monoclonal Antibodies by Human—Human Hybridomas: Their Application to Studies of Autoimmune Diseases | |
| JPH06189750A (ja) | ヒト単クローン性抗肺ガン細胞抗体を産生するハイブリドーマ |